In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties

In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties

Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technologyAccelerated implementation of strategy through better monetization of technology and transitioning to an asset-lighter business modelAgreement includes approximately US$ 350 m…

Evotec SE (EVO) Stock Analysis: Unveiling A 34% Potential Upside In The Biotech Frontier

Evotec SE (NASDAQ: EVO), a prominent player in the healthcare sector, specifically within the niche of drug manufacturing, stands out as an intriguing opportunity for investors with a penchant for the pharmaceutical and biotech industries. Headquartered in Hamburg, Germany, Evotec SE is a drug discovery and development powerhouse, actively engaged in collaborations across the globe to innovate within therapeutic areas such as oncology, diabetes,…